Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Long-Term Deferred Tax (2016 - 2025)

Avanos Medical's Long-Term Deferred Tax history spans 10 years, with the latest figure at $6.6 million for Q3 2024.

  • For Q3 2024, Long-Term Deferred Tax rose 53.49% year-over-year to $6.6 million; the TTM value through Sep 2024 reached $6.6 million, up 53.49%, while the annual FY2023 figure was $6.5 million, 41.3% up from the prior year.
  • Long-Term Deferred Tax for Q3 2024 was $6.6 million at Avanos Medical, up from $6.3 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $61.9 million in Q2 2021 and bottomed at $4.3 million in Q3 2023.
  • The 5-year median for Long-Term Deferred Tax is $10.0 million (2020), against an average of $12.4 million.
  • The largest annual shift saw Long-Term Deferred Tax surged 342.14% in 2021 before it plummeted 82.07% in 2022.
  • A 5-year view of Long-Term Deferred Tax shows it stood at $10.0 million in 2020, then changed by 0.0% to $10.0 million in 2021, then plummeted by 54.0% to $4.6 million in 2022, then surged by 41.3% to $6.5 million in 2023, then increased by 1.54% to $6.6 million in 2024.
  • Per Business Quant, the three most recent readings for AVNS's Long-Term Deferred Tax are $6.6 million (Q3 2024), $6.3 million (Q2 2024), and $6.3 million (Q1 2024).